#Innovent hashtag - Bluesky

@newsen.bsky.social

1 week ago

Innovent Biologics Initiates Phase 3 Trial for Gout Drug IBI128 to Improve Patient Outcomes Innovent Biologics has commenced a Phase 3 study for IBI128, a novel gout treatment, aiming to provide enhanced care for gout patients in China.

Innovent Biologics Initiates Phase 3 Trial for Gout Drug IBI128 to Improve Patient Outcomes #China #Suzhou #Gout_Treatment #Innovent #IBI128

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Innovent Doses First Participant in Pivotal Phase 3 Clinical Trial for IBI354 Targeting HER2-Positive Breast Cancer Innovent Biologics has announced the initiation of a Phase 3 trial to evaluate IBI354, a promising treatment for HER2-positive breast cancer, highlighting its potential efficacy and safety.

Innovent Doses First Participant in Pivotal Phase 3 Clinical Trial for IBI354 Targeting HER2-Positive Breast Cancer #China #Suzhou #HER2-positive #Innovent #IBI354

0 0 0 0

AktieGo

@aktiego.bsky.social

1 month ago

Innovent Biologics and Eli Lilly announce a new collaboration to advance cancer and immune therapies. $350M upfront and up to $8.5B in milestones highlight confidence in Innovent’s R&D engine.

#Biotech #Healthcare #Innovation #Oncology #innovent #Community #GlobalHealth

0 0 0 0

Bizniz Insider PH

@biznizinsiderph.bsky.social

1 month ago

Innovent and Lilly Launch Breakthrough $8.5B Global Drug Collaboration - AktieGo Innovent Biologics has entered into a new strategic collaboration with Eli Lilly aimed at developing next-generation medicines for cancer and immune-related diseases, deepening a partnership that has ...

Innovent Biologics and Eli Lilly are expanding their decade‑long partnership. The new model accelerates antibody programs from discovery to global commercialization, with....

aktiego.com/innovent-and...

#Biotech #Healthcare #Innovation #innovent #Community #GlobalHealth

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment The FDA has granted Innovent's IBI3003 Fast Track Designation for treating relapsed multiple myeloma, enhancing development and approval speeds.

Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment #United_States #San_Francisco #Multiple_Myeloma #Innovent #IBI3003

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Lummus Technology's Strategic Investment in InnoVent Promotes Tire Recycling Innovations Globally Lummus Technology invests in InnoVent Renewables to boost global tire recycling, leveraging proven methods for a sustainable future.

Lummus Technology's Strategic Investment in InnoVent Promotes Tire Recycling Innovations Globally #USA #Houston #Innovent #Lummus_Technology #Tire_Recycling

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Innovent and Ollin Biosciences Achieve Milestone Results in Study of Diabetes-Related Eye Disease Treatment Innovent Biologics and Ollin Biosciences have demonstrated promising results in a head-to-head study of a new treatment for diabetic macular edema.

Innovent and Ollin Biosciences Achieve Milestone Results in Study of Diabetes-Related Eye Disease Treatment #None #San_Francisco #Innovent #Ollin_Biosciences #IBI324

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Innovent's TABOSUN®: A New Era in Neoadjuvant Treatment for Colon Cancer in China Innovent's TABOSUN® gains NMPA approval as China's first domestic CTLA-4 monoclonal antibody for treating MSI-H/dMMR colon cancer, promising improved patient outcomes.

Innovent's TABOSUN®: A New Era in Neoadjuvant Treatment for Colon Cancer in China #China #Suzhou #TYVYT® #Innovent #TABOSUN®

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Mazdutide Shows Promising Weight Loss Outcomes in Chinese Adolescents with Obesity Innovent Biologics has revealed significant findings from a Phase 1b trial on mazdutide, a treatment for obesity in Chinese adolescents, showcasing impressive weight loss results.

Mazdutide Shows Promising Weight Loss Outcomes in Chinese Adolescents with Obesity #China #Suzhou #obesity #Innovent #Mazdutide

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Innovent's PECONDLE® Phase 3 Study Clears Key Efficacy Endpoints for Psoriasis Treatment Success Innovent Biologics announces the successful completion of Phase 3 clinical trials for PECONDLE®, offering a promising long-term solution for psoriasis management by meeting all primary efficacy endpoints.

Innovent's PECONDLE® Phase 3 Study Clears Key Efficacy Endpoints for Psoriasis Treatment Success #China #Suzhou #Psoriasis #Innovent #PECONDLE

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma Innovent Biologics presents initial findings from its first-in-human trial of the trispecific antibody IBI3003 for relapsed multiple myeloma at ASH 2025.

Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent's PECONDLE® Becomes China's First Approved IL-23p19 Monoclonal Antibody Innovent's PECONDLE® (picankibart injection) is the first IL-23p19 monoclonal antibody approved in China for treating moderate-to-severe psoriasis.

Innovent's PECONDLE® Becomes China's First Approved IL-23p19 Monoclonal Antibody #China #Suzhou #Psoriasis #Innovent #PECONDLE

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

4 months ago

Innovent files high-dose mazdutide for obesity in China Innovent has filed a new high-strength version of its weight-loss drug mazdutide in China, aiming to help people with severe obesity.

#Innovent has filed a new high-strength version of its #weightloss drug mazdutide in #China that it says could meet a clinical need in people living with moderate-to-severe #obesity.

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent's Mazdutide 9 mg Shows Promising Efficacy in Weight Management for Chinese Adults Innovent Biologics' Mazdutide 9 mg has demonstrated remarkable effectiveness, achieving up to 20.1% weight loss in Chinese participants after a Phase 3 clinical trial, addressing obesity issues.

Innovent's Mazdutide 9 mg Shows Promising Efficacy in Weight Management for Chinese Adults #China #Suzhou #obesity #Innovent #Mazdutide

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Innovent and SanegeneBio Share Promising Phase 1 Data for IBI3016 at AHA 2025 Innovent and SanegeneBio unveil Phase 1 clinical data for IBI3016 at AHA 2025, showcasing its potential to treat hypertension effectively.

Innovent and SanegeneBio Share Promising Phase 1 Data for IBI3016 at AHA 2025 #China #Suzhou #Innovent #SanegeneBio #IBI3016

0 0 0 0

Business AM

@businessam.bsky.social

4 months ago

Chinees bedrijf Innovent daagt grote spelers Novo Nordisk en Eli Lilly met hun eigen medicatie voor gewichtsverlies Key takeaways Innovent Biologics, een Chinees farmaceutisch bedrijf, heeft veelbelovende resultaten aangekondigd van een klinische studie in een laat stadium waarin zijn GLP-1 injectie, mazdutide, wordt vergeleken met semaglutide van Novo Nordisk. Aan het onderzoek, dat bekend staat als DREAMS-3, namen patiënten met type 2-diabetes en obesitas deel. De onderzoekers evalueerden verschillende doses van de […]

Chinees bedrijf Innovent daagt grote spelers Novo Nordisk en Eli Lilly met hun eigen medicatie voor gewichtsverlies #Innovent #NovoNordisk #EliLilly #Gewichtsverlies #Diabetes

0 0 0 0

Business AM - FR

@businessam-fr.bsky.social

4 months ago

La société chinoise Innovent défie les géants Novo Nordisk et Eli Lilly avec son propre médicament amaigrissant Principaux renseignements Innovent Biologics, une société pharmaceutique chinoise, a annoncé les résultats prometteurs d’un essai clinique de stade avancé comparant son injection de GLP-1, le mazdutide, au semaglutide de Novo Nordisk. L’étude, connue sous le nom de DREAMS-3, portait sur des patients atteints de diabète de type 2 et d’obésité. Les chercheurs ont évalué différentes […]

La société chinoise Innovent défie les géants Novo Nordisk et Eli Lilly avec son propre médicament amaigrissant #Innovent #Médicament #Amaigrissement #DiabèteType2 #Obésité

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Innovent's Mazdutide Outperforms Semaglutide in Phase 3 Diabetes Trial Innovent's latest Phase 3 clinical trial highlights Mazdutide's superior efficacy over Semaglutide in controlling glycemic levels and reducing weight in diabetes patients.

Innovent's Mazdutide Outperforms Semaglutide in Phase 3 Diabetes Trial #China #Suzhou #Semaglutide #Innovent #Mazdutide

0 0 0 0

InfiniTech Life ｜無限テクノロジーと生きる未来

@cryptostart.bsky.social

5 months ago

武田×Innovent：AI創薬と次世代がん治療、1.1兆円連携の全貌 | AI News Innoventと武田がAI創薬で1.1兆円超のグローバル提携！次世代がん治療の未来を拓く。開発・医療業界への影響と全貌を深掘り解説。

AIクリエーターの道ニュース難治性がん治療に新時代！Innoventと武田が1.1兆円超のAI創薬グローバル連携を発表。その全貌と業界への影響を速報。 #AI創薬 #武田薬品 #Innovent

詳しくはこちら↓↓↓
gamefi.co.jp/2025/10/22/f...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Innovent Biologics Launches Innovative Cancer Treatment Platforms at Oncology R&D Day Innovent Biologics introduced groundbreaking cancer treatment platforms at its Oncology R&D Day, showcasing significant advancements in immuno-oncology and ADC technology.

Innovent Biologics Launches Innovative Cancer Treatment Platforms at Oncology R&D Day #China #Suzhou #Cancer_Treatment #Innovent #Oncology_R&D

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Hori Reappointed as President of Japan Exhibition Association Masato Hori, CEO of Innovent, re-elected as the President of the Japan Exhibition Association to support industry growth and collaboration.

Hori Reappointed as President of Japan Exhibition Association #Japan #Tokyo #Innovent #Japan_Exhibition_Association #Masato_Hori

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Innovent's DREAMS-1 Study of Mazdutide Presented at ADA 85th Session Innovent Biologics presented the Phase 3 DREAMS-1 study results of Mazdutide at the ADA 85th Scientific Sessions, highlighting its dual benefits for diabetes treatment.

Innovent's DREAMS-1 Study of Mazdutide Presented at ADA 85th Session #China #Suzhou #Innovent #Mazdutide #ADA_85

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Innovent's Groundbreaking Research on Biomedicine to Shine at ADA 85th Scientific Sessions Innovent Biologics will present significant findings on mazdutide and IBI3030 at the ADA 85th Scientific Sessions. Discover their impact on diabetes treatment!

Innovent's Groundbreaking Research on Biomedicine to Shine at ADA 85th Scientific Sessions #China #Suzhou #Innovent #Mazdutide #IBI3030

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Innovent Biologics Unveils Promising Clinical Data for IBI354 During ASCO 2025 At the ASCO 2025 annual meeting, Innovent Biologics presented promising clinical data for IBI354, a novel anti-HER2 ADC for advanced tumors.

Innovent Biologics Unveils Promising Clinical Data for IBI354 During ASCO 2025 #China #Suzhou #Innovent #IBI354 #ASCO2025

0 0 0 0

All Namibian News

@namibiannews.bsky.social

10 months ago

Namibia: Standard Bank lends $106m for Innovent’s Diaz Wind project - African Energy Namibia: Standard Bank lends $106m for Innovent’s Diaz Wind project African Energy

#Namibia #StandardBank #Innovent #DiazWind #RenewableEnergy

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Groundbreaking Phase 3 Study on Mazdutide Signals New Hope for Obesity Treatment in China A pivotal Phase 3 clinical study of mazdutide, an innovative dual agonist, shows promising results for obesity treatment in China, pushing for tailored strategies in managing obesity.

Groundbreaking Phase 3 Study on Mazdutide Signals New Hope for Obesity Treatment in China #China #Suzhou #Innovent #NEJM #Mazdutide

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

Innovent Launches Groundbreaking Bispecific and Tri-specific Antibodies at AACR 2025 Discover the latest preclinical data on Innovent's innovative bispecific and tri-specific antibodies presented at AACR 2025, emphasizing their therapeutic potential.

Innovent Launches Groundbreaking Bispecific and Tri-specific Antibodies at AACR 2025 #USA #Chicago #Innovent #Bispecific_Antibodies #Tri-specific_Antibodies

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago